Apostolos Zaravinos, Myrtani Pieri, Nikos Mourmouras, Natassa Anastasiadou, Ioanna Zouvani, Dimitris Delakas, Constantinos Deltas Department of Biological.

Slides:



Advertisements
Similar presentations
Cedars Sinai Medical Center
Advertisements

Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
Cluster analysis of networks generated through homology: automatic identification of important protein communities involved in cancer metastasis Jonsson.
ONCOMINE: A Bioinformatics Infrastructure for Cancer Genomics
Figure S1. ID#1 Lipid Metabolism, Small Molecule Biochemistry, Drug Metabolism.
Technische Universität München Cancer biomarker discovery by chemical and quantitative proteomics Sebastian Berger, B. Sc., Center of Life and.
Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated With Metastatic Disease Kevin Paiz-Ramirez.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.
Bayesian integration of biological prior knowledge into the reconstruction of gene regulatory networks Dirk Husmeier Adriano V. Werhli.
METHODS This project is an evidence based literature review conducted using the databases of Medline, AbstractsFirst, and Cochrane. The search terms used.
Molecular Biomarkers in Radiotherapy of Cervical Cancer A collaboration project between Department of Gynecologic Oncology and Department of Radiation.
Unit 1: The Language of Science  communicate and apply scientific information extracted from various sources (3.B)  evaluate models according to their.
Identification of network motifs in lung disease Cecily Swinburne Mentor: Carol J. Bult Ph.D. Summer 2007.
EnrichNet: network-based gene set enrichment analysis Presenter: Lu Liu.
Molecular classification of renal cell carcinoma subtypes using microRNA signatures Zaravinos A 1, Lambrou GI 2, Mourmouras N 3, Delakas D 3, Deltas C.
BIOMARKERS Diagnostics and Prognostics. OMICS Molecular Diagnostics: Promises and Possibilities, p. 12 and 26.
Bioinformatics Brad Windle Ph# Web Site:
Huidi Liu, M.D. & Ph.D Genomics Research Centre Harbin Medical University, China Reduced expression of SOX7 in ovarian cancer: a novel.
MicroRNA implication in urinary bladder cancer A. Zaravinos 1, J. Radojicic 3, G.I. Lambrou 2, D. Volanis 1,4, D. Delakas 4, E.N. Stathopoulos 3, D.A.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
S factor  body weight during WM  body weight during ER Supplementary figure 1: S factor distribution in each diet. S.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Construction of cancer pathways for personalized medicine | Presented By Date Construction of cancer pathways for personalized medicine Predictive, Preventive.
Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.
SP Cancer Metastasis Summary Hypothesis: We hypothesize that miRNAs regulate breast cancer cell invasiveness and metastasis by synergistically targeting.
Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.
DIFFERENTIALLY EXPRESSED GENES AND THEIR ASSOCIATED NETWORKS IN CLEAR-CELL RENAL CELL CARCINOMA (RCC) Apostolos Zaravinos and Constantinos C. Deltas Molecular.
Decoding the Network Footprint of Diseases With increasing availability of data, there is significant activity directed towards correlating genomic, proteomic,
Gene set analyses of genomic datasets Andreas Schlicker Jelle ten Hoeve Lodewyk Wessels.
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Supplemental Figure 2. IPA Gene Network Analysis. The top gene networks for DEGS more highly expressed (Panels A- B) and less highly expressed (Panels.
CBioPortal Web resource for exploring, visualizing, and analyzing multidimentional cancer genomics data.
Case Study: Characterizing Diseased States from Expression/Regulation Data Tuck et al., BMC Bioinformatics, 2006.
Eigengenes as biological signatures Dr. Habil Zare, PhD PI of Oncinfo Lab Assistant Professor, Department of Computer Science Texas State University 5.
NCode TM miRNA Analysis Platform Identifies Differentially Expressed Novel miRNAs in Adenocarcinoma Using Clinical Human Samples Provided By BioServe.
Use of gene expression to identify heterogeneity of metastatic behavior among high-grade pleomorphic soft tissue sarcomas Keith Skubitz 1, Princy Francis.
Introduction to Oncomine Xiayu Stacy Huang. Oncomine is a cancer-specific microarray database and has a web-based data-mining platform aimed at facilitating.
Triple negative (TN) vs. positive (TP) breast cancer (BC) analysis with public genomic data yields AGR3 as a biomarker Anita Umesh, Jenny Park, James Shima,
Raphael Sandaltzopoulos, PhD, MBA Professor at MBG (Molecular Biology) Lab. of Gene Expression, Molecular Diagnosis and Modern Therapeutics,
ARCH/VCDE F2F BoF And the Presentation Subtitle Goes Here Ravi Madduri December 2008.
R3 조 욱 Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer Articles LEI ZHANG, JAMES J. FARRELL, HUI ZHOU, DAVID ELASHOFF,
David Amar, Tom Hait, and Ron Shamir
miRNA-targets cross-talks: key players in glioblastoma multiforme
#4826 Cancer/testis antigen expression pattern is a potential biomarker for prostate cancer aggressiveness Luciane T. Kagohara1, Prakash Kulkarni1, Takumi.
1. SELECTION OF THE KEY GENE SET 2. BIOLOGICAL NETWORK SELECTION
MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma
* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,
Profiling of follicular fluid microRNAs in high and low Antral Follicle Count ovaries in cattle Rolando Pasquariello1,2, Nadia Fiandanese2, Andrea Viglino2,
Volume 15, Pages (February 2017)
Cancer, reproductive system diseases, lipid metabolism 48 22
Parimal Samir1, Rahul2, James C. Slaughter3, Andrew J. Link1,4,5, *
Integrated microRNA-mRNA profiling identifies molecular biomarkers in bladder outlet obstruction-induced lower urinary tract dysfunction Fiona C. Burkhard1,
European Urology Focus
Impact of Formal Methods in Biology and Medicine
Impact of Formal Methods in Biology and Medicine
4- Protein identification
Loyola Marymount University
Volume 25, Issue 3, Pages (March 2017)
A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non–Small-Cell Lung Cancer (NSCLC) Bronchoscopy.
miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma
Volume 139, Issue 3, Pages (December 2015)
Loyola Marymount University
János Fekete, Balázs Győrffy
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma E Tina1, S Prosén2, S Lennholm3, G.
Loyola Marymount University
Volume 16, Issue 11, Pages (September 2016)
Loyola Marymount University
Loyola Marymount University
Presentation transcript:

Apostolos Zaravinos, Myrtani Pieri, Nikos Mourmouras, Natassa Anastasiadou, Ioanna Zouvani, Dimitris Delakas, Constantinos Deltas Department of Biological Sciences, Molecular Medicine Research Center (MMRC) University of Cyprus, Kallipoleos 75, 1678, Nicosia, Cyprus. Contact: publication can be reached at: Clear cell renal cell carcinoma (ccRCC) represents the most common subtype (83%) of RCC. It is one of the most therapy-resistant carcinomas, responding very poorly or not at all to radiotherapy, hormonal therapy and chemotherapy. We hypothesized that a meta-analysis of several gene expression datasets of ccRCC can give a potentially significant list of co-deregulated genes (co-DEGs) in ccRCC, which is important to define pathways in which the genes of interest are involved. To increase the likelihood of revealing truly significant deregulated genes, which should have higher potentials to be used as novel markers for the disease, we analyzed their expression profile over 5 independent studies, greatly increasing the significance of results. We performed a meta-analysis of 5 publicly available gene expression datasets and identified a list of co-deregulated genes, for which we performed extensive bioinformatic analysis coupled with experimental validation on the mRNA level. Gene ontology enrichment showed that many proteins are involved in response to hypoxia/oxygen levels and positive regulation of the VEGFR signaling pathway. KEGG analysis revealed that metabolic pathways are mostly altered in ccRCC. Similarly, Ingenuity Pathway Analysis showed that the antigen presentation, inositol metabolism, pentose phosphate, glycolysis/gluconeogenesis and fructose/mannose metabolism pathways are altered in the disease. Cellular growth, proliferation and carbohydrate metabolism, were among the top molecular and cellular functions of the co-deregulated genes. qRT-PCR validated the deregulated expression of several genes in Caki-2 and ACHN cell lines and in a cohort of ccRCC tissues. NNMT and NR3C1 increased expression was evident in ccRCC biopsies from patients using immunohistochemistry. ROC curves evaluated the diagnostic performance of the top deregulated genes in each dataset. We show that metabolic pathways are mostly deregulated in ccRCC and we highlight those being most responsible in its formation. Our data corroborate that kidney cancer cells manipulate more than one molecular mechanisms and a number of biological pathways to achieve their aggressive phenotype. Renal carcinoma is made up of a number of cancers that occur in the kidney, each having a different histology and caused by different genes. Here, we highlight that ccRCC is fundamentally a metabolic disorder. Data mining strategy for selecting ccRCC marker genes was based on the Oncomine v4.4.3 cancer microarray platform. Concept filters were used to identify DEGs between ccRCC and the normal kidney. Pathway analysis was performed with Ingenuity Pathway Analysis (IPA v7). Gene expression validation was performed in Caki-2 and ACHN ccRCC cell lines, compared to the corresponding levels in the HEK-293 cells using qRT-PCR. Gene expression validation was also performed by qRT-PCR and Immunohistochemistry (IHC) in a cohort of 10 patients with sporadic ccRCC who underwent a radical tumour nephrectomy. Receiver Operating Characteristic (ROC) curves analysis was used to evaluate the diagnostic performance of the top 20 deregulated genes in each microarray dataset. The MAS5-calculated Signal intensity values extracted from each dataset were used for the analysis. Sensitivity and specificity scores defining the area under the curve (AUC) were used for each candidate gene in order to discriminate between those individuals with ccRCC and those without the disease. Further Gene Ontology (GO), KEGG pathways, Wikipathways and Pathway Commons Analysis was performed using WebGestalt ( BACKGROUND / OBJECTIVE METHODS RESULTS CONCLUSIONS Altered metabolic pathways in clear cell renal cell carcinoma: A meta-analysis and validation study focused on the deregulated genes and their associated networks 2. Co-up (A) and co-down (B) regulated genes in ccRCC vs. their non-tumor kidney tissue. 1. Workflow of the study. Initially, Five Oncomine microarray datasets were compared and the co-DEGs among them were retrieved. Next, the canonical pathways in which these co-DEGs are implicated were identified, as well as the networks that they form, and the top deregulated molecules among them. Validation of the deregulated expression levels of these genes was performed both in ccRCC cell lines, as well as in a cohort of ccRCC patients. IHC was performed in biopsies from the patient cohort for the top deregulated genes. ROC analysis evaluated the discriminatory potential of the candidate biomarkers. Further enrichment analysis was performed for the co-DEGs. 3. IPA canonical pathways of the top 1% deregulated genes in ccRCC vs. the normal tissue samples, among the 5 datasets. Overall, the majority of our deregulated pathways were related to metabolic processes. 4. The top 5 IPA gene networks (26≤score≤35) were associated with: 1) Hematological system development and function, cell-to- cell signaling and interaction, reproductive system development and function; 2) Carbohydrate metabolism, cell death, endocrine system disorders; 3) Carbohydrate metabolism, small molecule biochemistry, cellular development; 4) Molecular transport, renal and urological disease, cellular function and maintenance; 5) Lipid metabolism, small molecule biochemistry, molecular transport. 5. ROC analysis of the top 20 DEGs in ccRCC vs. the normal kidney using each datasets extracted MAS5- calculated signal intensity values. 8. Volcanoplot of the DEGs in a cohort of 10 ccRCC patient samples compared to the adjacent normal kidney samples and ROC analysis of the validated DEGs. 7. In the patients with confirmed ccRCC, serial sections showed stronger NNMT and NR3C1 immunoreactivity as compared to the controls. 6. The Volcano-plots depict the DEGs in ACHN and Caki-2 cell lines compared to the HEK-293 cells..